Steatohepatitis/Metabolic Liver Disease News

WASHINGTON — Glucagon-like peptide-1 receptor agonists were associated with lower risk for progression to cirrhosis and hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease and type 2 diabetes.

WASHINGTON — Patients with obesity and metabolic dysfunction-associated fatty liver disease taking glucagon-like peptide-1 receptor agonists had lower risk for all-cause mortality and major cardiovascular events, according to a presenter.

Adults with type 1 diabetes who play sports have less insulin resistance and are less likely to develop metabolic dysfunction-associated steatotic liver disease, according to study findings.

An analysis of the global online conversations of more than 1,600 healthcare professionals has revealed celebration at news of the approval of the first treatment for adults with metabolic dysfunction-associated steatohepatitis.

Food insecurity was associated with lower odds of metabolic dysfunction-associated steatotic liver disease among patients with HIV, although the presence of diabetes increased the odds of fibrosis in this population, according to data.

Vibration-controlled transient elastography-based Agile scores accurately predicted liver-related events in patients with metabolic dysfunction-associated steatotic liver disease and “may be suitable alternatives” to routine liver biopsy.

In this video, Sarah L. Maxwell, MD, and Janet M. Wojcicki, PhD, MPH, discuss a reported link between food insecurity at age 4 years and an increased risk for metabolic dysfunction-associated steatotic liver disease among Latino children.

Daily low-dose aspirin “significantly reduced” hepatic fat quantity at 6 months compared with placebo among patients with metabolic dysfunction-associated steatotic liver disease, according to preliminary trial results published in JAMA.

While the CDC estimated that excessive alcohol use contributed to approximately 178,000 U.S. deaths each year from 2020 to 2021, an emerging lifestyle trend may help counter those statistics in the years ahead.

Efruxifermin with a glucagon-like peptide-1 receptor agonist was well-tolerated and reduced hepatic fat fraction and noninvasive markers of fibrosis among patients with metabolic dysfunction-associated steatohepatitis and type 2 diabetes.